Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Sponsor: Anhui Provincial Hospital
Summary
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has been demonstrated to be able to increase the survival of patients with metastatic driven-genes negative non-small cell lung cancer. Various dose-fraction of radiotherapy could exert different effects on the immune system. Ablative-dose could induce immunogenic cell death through the activation of CD8+(Cluster of Differentiation) T cells. Low-dose could modulate immune microenvironment from immunosuppression to inflammatory anti-tumor phenotype. This trial is designed to validation the safety and primary efficacy of the combination of hybrid dose-fraction radiotherapy with ICI for metastatic driven-genes negative non-small cell lung cancer patients.
Official title: Hybrid Dose-fraction Radiotherapy for Metastatic Driven-genes Negative Non-small Cell Lung Cancer: A Phase II Multi-institutional Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2022-05-09
Completion Date
2025-05-01
Last Updated
2026-08-14
Healthy Volunteers
No
Conditions
Interventions
Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
Locations (1)
Anhui Provicial Hospital
Hefei, Anhui, China